If true it boggles the mind. pic.twitter.com/ngAVQkTNib
— Ed ☯️Free Thinker & Oracle (@DowdEdward) March 11, 2022
In a related note, if you know who Justin Bieber is, his wife, who is also Alec Baldwin’s niece, just had a stroke.
TMZ reports the model, 25, was admitted to a Palm Springs area hospital a few days ago after suffering a “medical emergency” that reportedly affected the way she moved. Her symptoms are said to be more typical of an older person, not of a runway pro in her mid-20s.
UPDATE: Ah, just a TIA. Hey, what 25 year old HASN’T started having Transient Ischemic Attacks and started the countdown to “the big one”, amirite? She has a one in three chance of having a major stroke within 12 months, IF you use pre-DeathInjection probabilities tied to natural old age. I’d say since we are dealing with an active poisoning known to cause strokes, her odds are far higher. Shaddap and get ya boostah!
MEANWHILE, it was announced today by Moderna that Stéphane Bancel, the psychopath founder and CEO of Moderna who knew all along that the mRNA injections were poisonous, has a “golden parachute” walk-away retirement package option worth $926 million dollars.
PLEASE read the ARSH 2016 article on Bancel and Moderna that I reprinted in full in which Bancel’s psychopathy is discussed at length, as is the openly-admitted toxicity of mRNA injections.
Delivery — actually getting RNA into cells — has long bedeviled the whole field. On their own, RNA molecules have a hard time reaching their targets. They work better if they’re wrapped up in a delivery mechanism, such as nanoparticles made of lipids. But those nanoparticles can lead to dangerous side effects, especially if a patient has to take repeated doses over months or years.
Novartis abandoned the related realm of RNA interference over concerns about toxicity, as did Merck and Roche…
“I would say that mRNA is better suited for diseases where treatment for short duration is sufficiently curative, so the toxicities caused by delivery materials are less likely to occur,” said Katalin Karikó, a pioneer in the field who serves as a vice president at BioNTech.